AB0729 Clinical and instrumental characteristics of patients with systemic sclerosis in different interval separated by scleroderma clinical trials consortium damage index (SCTC-DI) in Russian cohort patients.
Authors: O. Ovsyannikova, O. Koneva, L. Garzanova, A. Khelkovskaia-Sergeeva, O. Desinova, M. Starovoytova, R. Shayakhmetova
Journal: Annals of the Rheumatic Diseases (2022)

Background Systemic sclerosis (SSc) is a complex disease having an incidence of 1-2 cases per 100,000. In SSc, inflammation leads to organ failure due to severe fibrosis of the skin and internal organs. At late stages, this disease is characterized by a profound decline in the quality of life and premature death [1]. The course of SSc is often one of progressive damage to multiple organs including the skin, joints, heart, lungs, gastrointestinal tract and kidneys. The scleroderma clinical trials consortium damage index (SCTC-DI): a new instrument to quantify organ damage in systemic sclerosis [2]. Objectives To use the scleroderma clinical trials consortium damage index (SCTC-DI) for pts with systemic sclerosis and highlight pts with different disease severity in Russian cohort patients. Methods Data from 96 patients with systemic sclerosis (mean age was 51,3±12,2; 63% have limited subset of the disease; 88% were female) all fulfilling the ACR criteria for SSc. Functional lung tests, high-resolution CT (HRCT), echocardiography, SSc activity (by the European Scleroderma Study Group (EScSG) activity index), HAQ, SHAQ, the six minute walk test (6MWT), scleroderma clinical trials consortium damage index (SCTC-DI) were evaluated. Total scores of SCTC-DI were categorized into groups (low damage score&lt;5, moderate damage score 6-12, high damage score ≥13). Other data collected including biological results (high-sensitivity C-reactive protein (hsCRP) and erythrocyte sedimentation rate (ESR). Statistical analysis: descriptive data are presented as means (±SD) or medians (with interquartile range [IQR]) for continuous variables, while categorical variables are expressed as counts and percentages. Univariate comparisons were made with 2-sample t tests. Results pts were divided into 3 groups in depend on total score of SCTC-DI. 77pts (80%) were into group 1 (with low damage score); 17 pts (18%) were into group 2 (with moderate damage score) and 2 pts (2%) were into group 3 (with high damage score). Baseline characteristics of the groups are presented in Table 1 Table 1. parameters Group1(n=77) (M±SD) Group2 (n=17)(M±SD) Group3 (n=2)(M±SD) P Age (months) 51.7±12.3 54.1±12.2 47±11.3 &gt;0.05 SSc formsLim 43 (55%) 12 (70%) 1 (50%) &gt;0.05 Gender: fem 69 (88%) 14 (82%) 2 (100%) Duration of dis.(years) 8.9±7.6 12.4±7.1 15±7 &gt;0.05 HAQ 0.83±0.68 1.14±0.653 1.62 &gt;0.05 SHAQ 1.174±0.704 1.3±0.76 1.5 &gt;0.05 6MWT 412±170 358±187 108 &gt;0.05 EScSG 1.81±1.44 2.14±1.44 0.5 &gt;0.05 hsCRPMED[25;75‰] 6.63±14.82.93 [1.2;5.62] 3.7±2.57 20.7±18.1 &gt;0.05 ESRMED[25;75‰] 16.7±21.412 [7;19] 20±31.614 [12;23] 71.5±92.6.871.5 [6;137] &gt;0.05 PAP 34.7±10.8 38±13.1 40±19.75 &gt;0.05 Left ventriculi infection fraction 69.9±7.3 66.7±5.7 64.5±3.5 &gt;0.05 FVC 97.3±14.68 64.7±17.3 43.3±5.8 Gr1 vsGr2Gr1vs Gr3p&lt;0.0001 DLco 60.9±16 36.4±9.5.3 44.3 Gr1 vsGr2p&lt;0.0001 FEV1 96.8±14.9 66.3±20.1 46.7±7.2 Gr1 vsGr2Gr1vs Gr3p&lt;0.0001 We didn’t find a lot of significant differences in between groups, but it could be noted that group 3 was younger and the severity of the parameters increased in groups moderate and high damage. We found that mean value of FVC, DLco and FEV1 were significant increased in group1. Conclusion the pts with moderate and high damage scores of SCTC-DI had worse clinical and instrumental characteristics than pts with low damage score. We could try to use scores of SCTC-DI as measures of SSc severity. References [1] Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med (2009) 360(19):1989–2003. 10.1056/NEJMra0806188 [2] Ferdowsi N, Huq M, et al. Development and validation of the Scleroderma Clinical Trial Consortium Damage index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis. Ann Rheum Dis 2019;0:1–10. doi:10.1136/annrheumdis-2018-214764. Disclosure of Interests None declared